ARF6 regulates neuron differentiation through glucosylceramide synthase

PLoS One. 2013;8(3):e60118. doi: 10.1371/journal.pone.0060118. Epub 2013 Mar 28.

Abstract

The small GTPase ADP ribosylation factor 6 (ARF6) mediates endocytosis and has in addition been shown to regulate neuron differentiation. Here we investigated whether ARF6 promotes differentiation of Neuro-2a neuronal cells by modifying the cellular lipid composition. We showed that knockdown of ARF6 by siRNA in Neuro-2a cells increased neuronal outgrowth as expected. ARF6 knockdown also resulted in increased glucosylceramide levels and decreased sphingomyelin levels, but did not affect the levels of ceramide or phospholipids. We speculated that the ARF6 knockdown-induced increase in glucosylceramide was caused by an effect on glucosylceramide synthase and, in agreement, showed that ARF6 knockdown increased the mRNA levels and activity of glucosylceramide synthase. Finally, we showed that incubation of Neuro-2a cells with the glucosylceramide synthase inhibitor D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP) normalized the increased neuronal outgrowth induced by ARF6 knockdown. Our results thus show that ARF6 regulates neuronal differentiation through an effect on glucosylceramide synthase and glucosylceramide levels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-Ribosylation Factor 6
  • ADP-Ribosylation Factors / genetics
  • ADP-Ribosylation Factors / metabolism*
  • Cell Differentiation / genetics
  • Cell Differentiation / physiology*
  • Cell Line
  • Glucosylceramides / metabolism
  • Glucosyltransferases / genetics
  • Glucosyltransferases / metabolism*
  • Humans
  • Neurons / cytology*
  • Neurons / metabolism*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sphingomyelins / metabolism

Substances

  • ADP-Ribosylation Factor 6
  • Glucosylceramides
  • Sphingomyelins
  • Glucosyltransferases
  • ceramide glucosyltransferase
  • ADP-Ribosylation Factors
  • ARF6 protein, human

Grants and funding

This study was supported by grants from the Swedish Research Council, the Swedish Heart and Lung Foundation, Torsten and Ragnar Söderbergs Foundations, the Swedish Diabetes Foundation, Novo Nordic Foundation, the Swedish Foundation for Strategic Research, and the EU program LipidomicNet. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.